161 related articles for article (PubMed ID: 15146424)
1. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide.
Cunnane G; Chan OT; Cassafer G; Brindis S; Kaufman E; Yen TS; Daikh DI
Arthritis Rheum; 2004 May; 50(5):1539-48. PubMed ID: 15146424
[TBL] [Abstract][Full Text] [Related]
2. Prevention and reversal of lupus in NZB/NZW mice by costimulatory blockade with adeno-associated virus-mediated gene transfer.
Ye X; Zhu T; Bastacky S; McHale T; Li J; Xiao X
Arthritis Rheum; 2005 Dec; 52(12):3975-86. PubMed ID: 16329128
[TBL] [Abstract][Full Text] [Related]
3. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of CTLA-4Ig and sirolimus on orthotopic lung-allograft survival and histology.
Ugurlu MM; Griffin MD; Tazelaar HD; McGregor CG
Transplantation; 2003 Aug; 76(3):489-95. PubMed ID: 12923433
[TBL] [Abstract][Full Text] [Related]
6. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
Kulkarni O; Eulberg D; Selve N; Zöllner S; Allam R; Pawar RD; Pfeiffer S; Segerer S; Klussmann S; Anders HJ
J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide.
Daikh DI; Wofsy D
J Immunol; 2001 Mar; 166(5):2913-6. PubMed ID: 11207238
[TBL] [Abstract][Full Text] [Related]
8. Regulation of immune function by calorie restriction and cyclophosphamide treatment in lupus-prone NZB/NZW F1 mice.
Sun D; Krishnan A; Su J; Lawrence R; Zaman K; Fernandes G
Cell Immunol; 2004 Mar; 228(1):54-65. PubMed ID: 15203320
[TBL] [Abstract][Full Text] [Related]
9. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
Sharabi A; Azulai H; Sthoeger ZM; Mozes E
Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.
Lui SL; Tsang R; Chan KW; Zhang F; Tam S; Yung S; Chan TM
Nephrol Dial Transplant; 2008 Sep; 23(9):2768-76. PubMed ID: 18445640
[TBL] [Abstract][Full Text] [Related]
11. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis.
Quezada SA; Eckert M; Adeyi OA; Schned AR; Noelle RJ; Burns CM
Arthritis Rheum; 2003 Sep; 48(9):2541-54. PubMed ID: 13130474
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice.
Lui SL; Yung S; Tsang R; Zhang F; Chan KW; Tam S; Chan TM
Lupus; 2008 Apr; 17(4):305-13. PubMed ID: 18413412
[TBL] [Abstract][Full Text] [Related]
13. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
[TBL] [Abstract][Full Text] [Related]
14. Treatment for lupus nephritis: a revisit.
Lai KN; Tang SC; Mok CC
Nephrology (Carlton); 2005 Apr; 10(2):180-8. PubMed ID: 15877679
[TBL] [Abstract][Full Text] [Related]
15. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition.
Schiffer L; Sinha J; Wang X; Huang W; von Gersdorff G; Schiffer M; Madaio MP; Davidson A
J Immunol; 2003 Jul; 171(1):489-97. PubMed ID: 12817034
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
17. Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide.
Ferrera F; Hahn BH; Rizzi M; Anderson M; Fitzgerald J; Millo E; Indiveri F; Shi FD; Filaci G; La Cava A
Arthritis Rheum; 2007 Jun; 56(6):1945-53. PubMed ID: 17530718
[TBL] [Abstract][Full Text] [Related]
18. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
19. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC
Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
